Learning
WHAT’S NEW
In part one of a series of articles on ibogaine clinics, researcher Leonard Pickard looks at the history and treatment protocols o...
Underscoring an anecdotal observation common among cannabis consumers, a group of researchers in Canada have released a new study ...
The Drug Enforcement Administration (DEA) last week proposed increasing its 2024 production quotas for research-grade psychedelic ...
POPULAR ARTICLES
Psilocybin reduces alcohol use by altering gene expression in brain’s reward center
Psilocybin reduces alcohol consumption in rats by altering specific brain pathways, suggesting potential for new treatments for al...
Read More
Challenges to a Company‚ Psilocybin Patent Highlight Contrasting Business Strategies for Developers of Psychedelic Therapies
Tactics used by Compass Pathways common to pharma companies pose ethical questions for the emerging psychedelics industry. Part on...
Read More
“Heartbreak” Is a Post-Divorce Exploration of Grief, Self-Discovery, and the Healing Power of Nature
When Outside contributing editor Florence Williams’s husband of 25 years left her, she paddled the Green River to process he...
Read More
Investors Are Debating Who Should Own the Future of Psychedelics
In a series of open letters and statements, investors have been debating how patents will shape the future—who will get to u...
Read More
FDA Greenlights University Research of Filament Psychedelic Drug
The U.S. Food and Drug Administration has granted approval for two major American universities to study the firm\'s psilocybin-der...
Read More
Origin Therapeutics to Begin Trading on the CSE Under the Symbol “ORIG”
The Company will commence trading on June 6, 2022 under the symbol “ORIG” on the Canadian Securities Exchange Vancouve...
Read More